Andere Sprachen Modalis Therapeutics Corporation

Aktien

A2P9BG

JP3922600006

4883

Verzögert Japan Exchange Andere Börsenplätze 03:34:14 15.05.2024			% 5 Tage	% 1. Jan.
71 ^JPY	0,00 %		-8,97 %	-42,74 %

07.05.	Modalis Therapeutics berichtet über Daten, die die Entwicklung eines transformativen Epigenom-Editing-Therapeutikums, MDL-101, unterstützen	CI
30.04.	Modalis Therapeutics Corporation präsentiert auf dem Global Cell & Gene Therapy Summit Daten, die die Entwicklung von transformativen Epigenome Editing-Medikamenten zur Behandlung von Muskeldystrophie unterstützen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)	07.05.
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	07.05.
Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	30.04.
Modalis Announces updated strategic plan and business consolidation of US operation	15.04.
Modalis Announces Partnership with Ginkgo Bioworks	15.04.
Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs	15.04.
Modalis Announces Partnership with Ginkgo Bioworks	12.04.
Modalis Therapeutics to Reduce Stated Capital and Capital Reserves	23.02.
Japanese Shares Continue to Track Wall Street Higher as Investor Caution Ahead of US Rate Decision Caps Gains	13.12.
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	13.12.
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	13.12.
Modalis and JCR Pharmaceuticals enter into joint research agreement	13.12.
Modalis Therapeutics Corporation announced that it has received ¥505.320864 million in funding from Evolution Capital Management LLC	30.11.
Modalis Therapeutics Corporation announced that it expects to receive ¥505.320864 million in funding from Evolution Capital Management LLC	07.11.
Modalis Therapeutics Corporation cancelled the transaction announced on September 11, 2023	28.09.23
Modalis Therapeutics Corporation announced that it expects to receive ¥18.77952 million in funding from China Silver Asset Management Hong Kong Limited	11.09.23
Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc	07.08.23
Modalis Therapeutics Corporation Receives Positive FDA Response for Pre-IND Review for MDL-101 Clinical Development	26.06.23
Modalis Therapeutics to Grant Stock Options	16.06.23
Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12.05.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Modalis Therapeutics Corporation

Aktien

A2P9BG

JP3922600006

4883

Andere Sprachen

Filter